The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia

References

• Kane JM. Management issues in schizophrenia. Taylor & Francis (A Martin Dunitz Book), London 2000
   Google Scholar
• Barbato, A. Schizophrenia and public health. World Health Organization, Geneva, 1998. Accessed 27 May 2005 [ available at:, , http://www.who.int/mental_health/media/en/55.pdf].
   Google Scholar
• National Institute of Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002. Accessed 27 May 2005 [ available at:, , http://www.nice.org.uk].
   Google Scholar
• McEvoy JP, Scheifler PL, Frances A. Expert Consensus Guideline Series. Treatment of schizophrenia. J Clin Psychiatry 1999; 60(Suppl 11)8–80
   Google Scholar
• Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. Springer-Verlag, New York 1998
   Google Scholar
• Fleischhacker WW, Hummer M. Do phase III trials have clinical value?. J Clin Psychopharmacol 1999; 19: 391–2
   PubMed Web of Science ®Google Scholar
• Norquist, G, Lebowitz B, Hyman S. Expanding the frontier of treatment research. Prevention and treatment. Vol. 2, Article 0001a,. 1999, posted 21 March. Accessed 27 May 2005 [available at:, , http://www.journals.apa.org/prevention/volume2/pre0020001a.html].
   Google Scholar
• Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 43: 262–5
   PubMedGoogle Scholar
• Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999; 60(Suppl 10)31–41
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002; 63(Suppl 13)5–11
   PubMed Web of Science ®Google Scholar
• Arvanitis, LA, Miller, BG, and the Seroquel Trial 13 study group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233–46.
   PubMed Web of Science ®Google Scholar
• Borison, RL, Arvanitis, LA, Miller, BG, and the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158–69.
   PubMed Web of Science ®Google Scholar
• Small, JG, Hirsch, SR, Arvanitis, LA, Miller, BG, Link, CGG, and the Seroquel Study Group. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549–57.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265–73
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, “Seroquel”) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105
   PubMed Web of Science ®Google Scholar
• Emsley, RA, Raniwalla, J, Bailey, PJ, Jones, AM, on behalf of the PRIZE Study Group. A comparison of the effects of quetiapine (“Seroquel”) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol, 2000;15:121–31.
   Google Scholar
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (revised 7 October 2000). HIV Clin Trials 2001;2:92–5.
   PubMedGoogle Scholar
• Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–912
   Web of Science ®Google Scholar
• Guy W. ECDEU. Assessment Manual for Psychopharmacology -Revised (DHEW Publ No ADM 76-338). US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD 1976; 218–22
   Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 334: 1–100
   Google Scholar
• Altman DG. Practical statistics for medical research. Chapman and Hall, London 1991
   Google Scholar
• Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry 2000; 61: 335–43
   PubMed Web of Science ®Google Scholar
• Srisurapanont, M, Disayavanish, C, Taimkaew, K. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews. 2000; CD000967.
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209–23
   PubMed Web of Science ®Google Scholar
• Wirshing, DA, Danovitch, I, Erhart, SM, Pierre, JM, Wirshing, WC. Update on atypicals: practical tips to manage common side effects. Curr Psychiatry, (accessed 3 April 2004) [ http://www.currentpsychiatry.com/2003_03/0303_antipsych.asp].
   Google Scholar
• De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003; 7: 59–66
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Zyprexa® olanzapine tablets/US prescribing information. 2005 [ http://pi lilly com/us/zyprexa-pi pdf].
   Google Scholar
• Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149: 689–90
   PubMed Web of Science ®Google Scholar
• Brecher, M, Leong, R, Osterling-Koskinen, L, Jones, M. Long-term weight change with quetiapine in schizophrenia: data review. Poster presented at the American Psychiatric Association Annual Meeting, Atlanta, , GA, USA; 2005. Poster NR262.
   Google Scholar
• Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004; 20: 1357–63
   PubMed Web of Science ®Google Scholar
• Goldstein, J, Paulsson, B, Sweitzer, D, Zhong, K. A review of the evidence for somnolence with quetiapine treatment. 158th Annual Meeting of the American Psychiatric Association, Atlanta, , GA, USA, 21–26, May; 2005. NR 259.
   Google Scholar
• Montejo Gonzalez, AL, Rico-Villademoros, F, Tafalla, M, Majadas, S, Spanish Working Group for the Study of Psychotropic-related Sexual Dysfunction. A 6-month prospective observational study on the effects of quetiapine on sexual functioning. J Clin Psychopharmacol 2005;25:533–538.
   PubMed Web of Science ®Google Scholar
• Sebastian CS, Glazer W, Buckley PF. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 2004; 11: 329–42
   PubMed Web of Science ®Google Scholar
• Mullen, J, Jibson, MD, Sweitzer, D, the QUEST Study Group. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839–54.
   PubMed Web of Science ®Google Scholar
• Montes, JM, Ciudad, A, Gascon, J, Gomez, JC, EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:667–74.
   PubMed Web of Science ®Google Scholar
• Lambert M, Haro JM, Novick D, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005; 111: 232–43
   PubMed Web of Science ®Google Scholar
• Tognoni G, Laporte JR. From clinical trails to drug utilization. Drug utilization studies. Methods and uses, MNG Dukes. World Health Organization, WHO Regional Publications European 1993
   Google Scholar
• Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry 2000; 61: 335–43
   PubMed Web of Science ®Google Scholar